Clinical trials: Motor Fluctuations
Parkinson's Disease
A Study of E2007 In Patients With Parkinson's Disease
Phase IIb open-label extension study for patients with Parkinson's Disease. All patients will receive active study drug. The study will involve outpatient visits only.
- Trial name
- NCT00427011
- Testing
- E2007
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eisai Inc.
Parkinson Disease, Motor Disorder
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
- Trial name
- NCT03608371
- Testing
- BTRX-246040
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Parkinson's Disease
Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea
To evaluate the efficacy of a fixed dose of Azilect® (1 mg/day) vs placebo as assessed by the change from baseline in mean total daily OFF time during 18 weeks of treatment in levodopa-treated Parkinson's Disease (PD) patients…
- Trial name
- NCT01268891
- Testing
- Azilect®
- Volunteers
- 132 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
The purpose of the study is to assess the efficacy and safety of XP21279/Carbidopa in comparison to Sinemet as well as evaluate the pharmacokinetics (PK) of levodopa after administration of XP21279/Carbidopa and Sinemet and to…
- Trial name
- NCT01171313
- Testing
- XP21279 and carbidopa (experimental), Sinemet (comparator)
- Where
- 12 sites in United States
- Volunteers
- 35 people
- Sponsor
- XenoPort, Inc.
Parkinson Disease
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa…
- Trial name
- ADOPTION (NCT04990284)
- Testing
- Opicapone, L-DOPA/DDCI
- Where
- 25 sites in Germany, Italy and 3 more
- Volunteers
- 106 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated…
- Trial name
- NCT00148512
- Testing
- 1. Tesofensine (NS 2330)
- Where
- 50 sites in Austria, France and 4 more
- Volunteers
- 254 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinsonism
Fall Risk Assessment in Parkinson's Disease Using Kinetikos Health
This is a single-center, prospective observational study aiming to validate the Kinetikos Health App for fall risk assessment in PD patients undergoing dopaminergic medication adjustments.
- Trial name
- PD_FALLRISK (NCT07257393)
- Testing
- No Intervention: Observational Cohort
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Parkinson's Disease
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
The purpose of the study is to assess the pharmacokinetics, pharmacodynamics, and safety of XP21279 sustained release formulation [administered with Lodosyn® (carbidopa)] and Sinemet® tablets in subjects with Parkinson's disease…
- Trial name
- NCT00914602
- Testing
- Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- XenoPort, Inc.
Idiopathic Parkinson's Disease
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
Parkinson's Disease is a major neurodegenerative disorder in which there is a progressive loss of dopamine-containing neurons. The understanding that PD is a syndrome of dopamine (DA) deficiency led to the introduction in the…
- Trial name
- SETTLE (NCT00627640)
- Testing
- Safinimide 50-100 mg/day
- Where
- 121 sites in United States, Australia and 19 more
- Volunteers
- 549 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor…
- Trial name
- ATLANTIS (NCT06055985)
- Testing
- UCB0022
- Where
- 61 sites in United States
- Volunteers
- 207 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa…
- Trial name
- NCT07432958
- Testing
- AP-472
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Appello Pharmaceuticals, Inc.
Parkinson Disease
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms.
- Trial name
- BOOST-PD (NCT07138560)
- Testing
- CREXONT ER
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- The Cleveland Clinic
Idiopathic Parkinson's Disease
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- NCT01777555
- Testing
- CVT-301
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 89 people
- Sponsor
- Acorda Therapeutics
Parkinson's Disease
DNS-7801 vs. Placebo in Parkinson's Disease
This is a randomized, double-blind, two-part placebo-controlled parallel group outpatient treatment study that will utilize standard Parkinson's Disease measures to evaluate the effect of DNS-7801
- Trial name
- PRIORITY (NCT03306329)
- Testing
- DNS-7801 (low-dose), DNS-7801 (high dose)
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dart NeuroScience, LLC
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Idiopathic Parkinson's Disease
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- SPAN-PD™ (NCT02240030)
- Testing
- CVT-301 Low Dose, CVT-301 High Dose
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 351 people
- Sponsor
- Acorda Therapeutics
Parkinson Disease
Bee Venom for the Treatment of Parkinson Disease
The purpose of this study is to evaluate the efficacy of repeated (monthly) injections of bee venom on motor symptoms of Parkinson's disease over a period of one year, also the potential effects of this treatment on disease…
- Trial name
- MIREILLE (NCT01341431)
- Testing
- bee venom
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parkinson's Disease With Motor Fluctuations
Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
The purpose of this study is to evaluate the long term safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
- Trial name
- NCT03185481
- Testing
- 1 mg QD to 15 mg QD PF-06649751, 3 mg QD to 15 mg QD PF-06649751, 7 mg QD to 15 mg QD PF-06649751
- Where
- 9 sites in United States
- Volunteers
- 5 people
- Sponsor
- Pfizer
Parkinson's Disease, Helicobacter Infections
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
The purpose of this study is to determine whether treatment of H. pylori (an infection of the stomach) improves treatment effectiveness in patients with Parkinson's disease and motor fluctuations.
- Conditions
- Parkinson's Disease, Helicobacter Infections, Motor Fluctuations
- Trial name
- NCT00664209
- Testing
- clartihromycin, amoxicillin, and omeprazole
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Los Angeles
Parkinson's Disease
A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor Fluctuations
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. A total of 276 eligible Parkinson's disease participants with motor fluctuations will be enrolled and assigned to one of three…
- Trial name
- NCT07585565
- Testing
- GM1
- Volunteers
- 276 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.